Cita APA (7a ed.)
Harmych, S. J., Joshi, N., Tanaka, H., Bogatcheva, G., Ramirez, M. A., Graves-Deal, R., . . . O'Grady, T. M. (2026). EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Cancer Letters, 654, -1.
Cita Chicago Style (17a ed.)
Harmych, Sarah J., et al. "EGFR S442 Ectodomain Mutation Confers Cetuximab Resistance That Can Be Overcome by ERBB2 Blockade with Trastuzumab-deruxtecan." Cancer Letters 654 (2026): -1.
Cita MLA (9a ed.)
Harmych, Sarah J., et al. "EGFR S442 Ectodomain Mutation Confers Cetuximab Resistance That Can Be Overcome by ERBB2 Blockade with Trastuzumab-deruxtecan." Cancer Letters, vol. 654, 2026, pp. -1.
Precaución: Estas citas no son 100% exactas.